ABSTRACT
Although the COVID-19 pandemic peaked in March/April 2020 in France, the prevalence of infection is barely known. Herein, we assessed using high-throughput methods the serological response against the SARS-CoV-2 virus of 1847 participants working in one institution in Paris.
In May-July 2020, 11% (95% CI: 9.7-12.6) of serums were positive for IgG against the SARS-CoV-2 N and S proteins and 9.5% (CI:8.2-11.0) were pseudo-neutralizer. The prevalence of immunization was 11.6% (CI:10.2-13.2) considering positivity in at least one assays. In 5% (CI:3.9-7.1) of RT-qPCR positive individuals, no systemic IgGs were detected. Among immune individuals, 21% had been asymptomatic. Anosmia and ageusia occurred in 52% of the IgG-positive individuals and in 3% of the negative ones. In contrast, 30% of the anosmia-ageusia cases were seronegative suggesting that the true prevalence of infection may reach 16.6%. In sera obtained 4-8 weeks after the first sampling anti-N and anti-S IgG titers and pseudo-neutralization activity declined by 31%, 17% and 53%, respectively with half-life of 35, 87 and 28 days, respectively.
The population studied is representative of active workers in Paris. The short lifespan of the serological systemic responses suggests an underestimation the true prevalence of infection.
Competing Interest Statement
YJ, SG and TR have patented the proluciferins (hikarazines) synthesis and uses (EP 3395803 / WO 2018197727, 2018) and applied for a patent which includes claims describing the LuLISA. FA and PC have applied for a patent claiming the PNT.
Clinical Trial
This study was registered and received ethical approval by the Comite de Protection des Personnes Mediterranee III (2020.04.18 bis 20.04.16.49458, 27/4/2020) registered in the clinical trial database (NCT04369066)
Funding Statement
This work was made possible thanks to the financial support obtained through the URGENCE nouveau coronavirus fundraising campaign of Institut Pasteur and the financial support of the Fondation Total. This study was funded in part by a grant from Fondation de France and by Institut Curie Institutional funding. The luciferin synthesis development has been supported by DARRI (ValoExpress 2016-2018). LuLISA development has been supported by IARP Pasteur-Carnot MI (2019-2020).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was registered and received ethical approval by the Comite de Protection des Personnes Mediterranee III (2020.04.18 bis 20.04.16.49458, 27/4/2020) registered in the clinical trial database (NCT04369066). Following informed consent, 18 years of age or older volunteer participant outside of any SARS-CoV-2 acute infectious episode in the last 7 days, working at one of the three Institut Curie locations (Paris, Orsay or Saint Cloud) completed a web-based questionnaire (Ennov Clinical) detailed in Supplementary Appendix 1 and 2.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Figure 1 revised Legend Figure 1 revised Authors and affiliation revised Supplementary Figure S6 revised Supplementary data Appendix 3 modified as requested: 1. Precise ages are replaced with an age range:19-38 or 39-82 in accordance with the median used in the text 2. Exact dates have been removed.
Data Availability
Detailed data are provided as spupplementary information
